RecruitingPhase 2NCT07211542

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of SHR-1905 Injection in Patients With Moderate to Severe Atopic Dermatitis

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd

Enrollment

75 participants

Start Date

Nov 7, 2025

Study Type

INTERVENTIONAL

Conditions

Moderate-to-severe Atopic Dermatitis

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SHR-1905 Injection and a drug called SHR-1905 Injection Blank Preparation for people with moderate-to-severe atopic dermatitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.